US Residents Only
For U.S. Audiences Only
Faced with Hutchinson-Gilford progeria syndrome (progeria) and processing-deficient progeroid laminopathies (PDPL)? Know Zokinvy® is the first and only disease-modifying treatment for these ultra-rare diseases.1,2
Michiel, 21 and Amber, 13, Belgium. Photo courtesy of The Progeria Research Foundation.
Eiger OneCare provides patients and caregivers with a dedicated, personalized support team to help with insurance coverage investigation, financial support options, and connecting with the Zokinvy pharmacy.
IMPORTANT SAFETY INFORMATION
ZOKINVY is contraindicated in patients taking:
INDICATION AND USAGE
ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: